Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families. Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development.
Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.
Company Details
- Employees
- 549
- Founded
- -
- Address
- 161 Oyster Point Blvd, South San Francisco,california 94080,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- denalitherapeutics.com
- HQ
- South San Francisco, California
Denali Therapeutics Questions
Denali Therapeutics's website is denalitherapeutics.com
Denali Therapeutics's LinkedIn profile is https://www.linkedin.com/company/denali-therapeutics
Denali Therapeutics has
549 employees.
View email and phone details for 549
employees at Denali Therapeutics.
Denali Therapeutics's industry is
Biotechnology Research
Denali Therapeutics's top competitors are
Amgen,
Cytokinetics,
Arcus Biosciences,
Bridgebio,
Gilead Sciences,
Arsenal Biosciences, Inc.,
Genentech,
Vertex Pharmaceuticals,
Allogene Therapeutics,
Maze Therapeutics.
Denali Therapeutics's categories are Biotechnology Research
Denali Therapeutics's founding year is 2015
